Chad Tang
University of Maryland, Baltimore(US)The University of Texas MD Anderson Cancer Center(US)The University of Texas MD Anderson Cancer Center(US)Johns Hopkins University(US)Guilin Medical University(CN)Zunyi Medical University(CN)Johns Hopkins Medicine(US)Inner Mongolia Electric Power (China)(CN)Guangxi Zhuang Autonomous Region Health and Family Planning(CN)Scripps MD Anderson Cancer Center(US)Spanish Oncology Genitourinary Group(ES)Heilongjiang Academy of Agricultural Machinery Engineering(CN)European Institute of Oncology(IT)The University of Texas Health Science Center at Houston(US)
Publications by Year
Research Areas
Prostate Cancer Treatment and Research, Prostate Cancer Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers, Advanced Radiotherapy Techniques, Health Systems, Economic Evaluations, Quality of Life
Most-Cited Works
- → The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors(2012)1,628 cited
- → Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study(2019)1,236 cited
- → State-of-the-art strategies for targeting the DNA damage response in cancer(2018)1,178 cited
- → Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma(2010)1,066 cited
- → Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study(2016)1,066 cited
- → Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies